For Charles Cathlin, the journey to founding Polaris Genomics began at Ground Zero. Stationed there after 9/11, he witnessed firsthand the invisible wounds of trauma that can persist long after physical debris is cleared [Illumina]. That experience seeded a question that has defined psychiatry for decades: why are there no molecular biomarkers to guide the diagnosis and treatment of mental health conditions, the way cardiology has troponin or oncology has PSA? His company, founded in 2017, is now building a platform to answer it, using genomics and AI to find biological signals for conditions like PTSD in a vial of blood [Polaris Genomics]. It is a bet on bringing objective, biology-based clarity to a field that has long relied on subjective patient interviews and clinician observation.
The ADAPT biomarker platform
The company's core technology is the ADAPT Neuropsychiatric Biomarker Discovery Platform. It uses a targeted gene panel, analyzed from a standard blood draw, to identify biomarker signatures associated with specific mental health conditions. The initial commercial wedge is a patented PTSD risk assay, which Polaris claims is first-to-market [Polaris Genomics]. The platform is designed to serve two primary customer groups: biotech and pharmaceutical companies developing new therapeutics, and researchers building next-generation diagnostics. The thesis is straightforward. By providing a measurable, biological readout of a patient's condition, the platform could help drug developers identify the right patients for clinical trials more precisely and potentially track a therapy's biological effect more objectively than subjective rating scales alone.
A veteran-led bet on precision mental health
The founding story and team composition are central to the company's identity and mission focus. Cathlin, the CEO, is a veteran, and the company is veteran-owned. The scientific leadership comes from co-founder and Chief Scientific Officer Tshaka Cunningham, who holds a PhD in molecular biology from Rockefeller University [Polaris Genomics]. This blend of mission-driven perspective and deep scientific expertise has attracted a notable, if relatively quiet, group of backers. To date, Polaris has raised approximately $3.4 million in seed funding from investors including Viking Global Investors, Wing Venture Capital, and Sanford Health, alongside non-dilutive support from Maryland's TEDCO [citybiz][TEDCO]. The company has also been through the Illumina Accelerator and maintains research collaborations with scientists at Mount Sinai and the Max Planck Institute of Psychiatry [Polaris Genomics].
| Funding Round | Amount | Lead Investor(s) / Source | Year |
|---|---|---|---|
| Seed | $2,000,000 | Undisclosed | 2020 [citybiz] |
| SSBCI Grant | $500,000 | TEDCO | 2023 [TEDCO] |
| Debt Financing | $250,000 | Undisclosed | 2023 [Crunchbase] |
The long road to clinical utility
For all its ambition, Polaris operates in one of the most challenging arenas in modern medicine. The path from a research-grade biomarker to a clinically validated tool cleared by the FDA for diagnosis is long, expensive, and fraught with scientific and regulatory hurdles. The company's current focus on selling its PTSD assay to researchers and pharma for R&D is a pragmatic first step, but it places them in a competitive landscape with entrenched players and emerging science. While not direct competitors offering the same service, companies like Genomic Health (now part of Exact Sciences) and Guardant Health have set a high bar for the clinical validation and commercial adoption of complex molecular diagnostics in oncology. In consumer genomics, 23andMe has explored mental health trait reporting, highlighting both the broad interest and the sensitivity of the category.
The risks for Polaris are not trivial, and they extend beyond typical startup execution challenges.
- Scientific validation. The core challenge is proving that the identified biomarkers are consistently and meaningfully linked to clinical outcomes across diverse populations. Peer-reviewed publications demonstrating this link will be a critical credibility milestone.
- Regulatory pathway. Navigating the FDA's requirements for a mental health diagnostic, especially one intended to inform treatment decisions, is a multi-year process requiring substantial capital and clinical trial data.
- Commercial adoption. Even with regulatory clearance, convincing payers to reimburse for a novel test and integrating it into the workflow of psychiatrists represents a significant behavioral change hurdle.
What standard of care looks like today
Understanding Polaris's potential impact requires a clear view of the current landscape for patients with conditions like PTSD. Today, diagnosis is almost entirely based on a clinical interview using structured guides like the Clinician-Administered PTSD Scale (CAPS). Treatment decisions,whether to start a medication like an SSRI, pursue trauma-focused psychotherapy, or try a newer modality,are made through a process of trial and observation, often over months. There are no routine blood tests, brain scans, or other objective measures to confirm the diagnosis, predict which treatment will work for which patient, or provide an early signal of recovery. This subjectivity can lead to diagnostic uncertainty, treatment delays, and frustration for patients seeking concrete answers. For the estimated 13 million Americans living with PTSD in a given year, the standard of care is a conversation, not a lab result. Polaris Genomics is betting that needs to change.
Sources
- [Illumina] Polaris Genomics seeks to reveal invisible wounds | https://www.illumina.com/company/news-center/feature-articles/polaris-genomics-seeks-to-reveal-invisible-wounds-.html
- [Polaris Genomics] Home - Polaris Genomics | https://polarisgenomics.com/
- [Polaris Genomics] Our Story | https://polarisgenomics.com/about-us/our-story/
- [citybiz] Mental Health Startup Polaris Genomics Gets $1 Million Backing | https://www.citybiz.co/mental-health-startup-polaris-genomics-gets-1-million-backing/
- [TEDCO, 2023-08] TEDCO Announces SSBCI Investment in Polaris Genomics | https://www.tedcomd.com/news-events/press-releases/2023/tedco-announces-ssbci-investment-polaris-genomics
- [Crunchbase] Polaris Genomics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/polaris-genomics-830d